Oxidized low-density protein, interleukin-6 and tumor necrosis factor alpha levels and paraoxonase activities in hypertensive patients;Hipertansiyon hastalarında okside düşük dansiteli lipoprotein, İnterlökin-6 ve tümör nekroz faktör-α düzeyleri ve paraoksonaz aktiviteleri

Turkish Journal of Pharmaceutical Sciences

Volumn 9, Issue 1, 2012, Pages 41-50

  Gönenç, Aymelek ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Hypertension; Inflammatory cytokines; Oxidative stress; Oxidized LDL; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SPECTROPHOTOMETRY;

EID: 84859542832     PISSN: 1304530X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lifton RP, Gharavi AG, Geller DS, Molecular mechanisms of human hypertension, Cell 104, 545-556,2001.
2. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Subtle acquired renal injury as a mechanism of saltsensitive hypertension, N Engl J Med 346, 913-923, 2002.
3. Messerli FH, Williams B, Ritz E, Essential hypertension, Lancet 370, 591-603, 2007.
4. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH, Left ventricular hypertrophy in hypertension: Prevalence and relationship to pathophysiologic variables, Hypertension 9 (Suppl II), 53-60, 1987.
5. Palatini P, Microalbuminuria in hypertension, Curr Hypertens Rep 5, 208-214, 2003.
6. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K, Arterial hypertension, microalbuminuria, and risk of ischemic heart disease, Hypertension 35, 898-903, 2000.
7. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE, Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension, N Engl J Med 323, 22-27, 1990.
8. Perticone F, Ceravolo R, Pujia A, Ventura G, Lacopino S, Scozzafava A, et al., Prognostic significance of endothelial dysfunction in hypertensive patients, Circulation 104, 191-196, 2001.
9. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G, Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension, J Cardiovasc Pharmacol 42,453-461,2003.
10. Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, et al., Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti oxidative stress effect in patients with essential hypertension, Hypertens Res 30, 307-313, 2007.
11. Becker LB, New concepts in reactive oxygen species and cardiovascular reperfusion physiology, Cardiovasc Res 61, 461-470, 2004.
12. Juránek I, Bezek S, Controversy of free radical hypothesis: reactive oxygen species-cause or consequence of tissue injury?, Gen Physiol Biophys 24, 263-278, 2005.
13. Witztum JL, Steinberg D, Role of oxidized low density lipoprotein in atherogenesis, J Clin Invest 88, 1785-1792, 1991.
14. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL, Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL, Arterioscler Thromb 14, 32-40, 1994.
15. Vindis C, Escargueil-Blanc I, Elbaz M, Marcheix B, Grazide MH, Uchida K, et al, Desensitization of platelet-derived growth factor receptor-beta by oxidized lipids in vascular cells and atherosclerotic lesions: prevention by aldehyde scavengers, Circ Res 98, 785-792, 2006.
16. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA, Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins, Curr Opin Lipidol 7, 69-76, 1996.
17. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al., Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?, Arterioscler Thromb Vase Biol 21, 1451-1457, 2001.
18. Uzun H, Karter Y, Aydin S, Curgunlu A, Şimşek G, Yücel R, et al., Oxidative stress in white coat hypertension; role of paraoxonase, J Hum Hypertens 18, 523-528, 2004.
19. Rosenblat M, Hayek T, Hussein K, Aviram M, Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy, Arterioscler Thromb Vase Biol 24, 175-180,2004.
20. Chae CU, Lee RT, Rifai N, and Ridker PM, Blood pressure and inflammation in apparently healthy men, Hypertension 38, 399-403, 2001.
21. Donners MM, Daemen MJ, Cleutjens KB, Heeneman S, Inflammation and restenosis: implications for therapy, Ann Med 35, 523-531, 2003.
22. Siwik DA, Colucci WS, Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium, Heart Fail Rev 9, 43-51, 2004.
23. Roland S, Keaney JF, Role of oxidative modification in atherosclerosis, Physiol Rev 84, 1381-1478,2004.
24. Miller YI, Choi SH, Fang L, Tsimikas S, Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis, Subcell Biochem 51, 229-251, 2010.
25. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas J, Economou M, Papadimitriou L, Stefanadis C, The association between pre-hypertension status and oxidative stres markers related to atherosclerotic disease: The ATTICA study, Atherosclerosis 192, 169-176, 2007.
26. Stiefe P, Argüelles S, Garcia S, Jimenez L, Aparicio R, Carneado J, Machado A, Ayala A, Effects of short-term supplementation with folic acid on different oxidative stress parameters in patients with hypertension, Biochimica et Biophysica Acta 1726, 152-159, 2005.
27. Konukoglu D, Firtina S, Serin O, Cavusoglu C, Relationship among plasma secretory phospholipase A2, oxidized low density lipoprotein & paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors, Indian J Med Res 129, 390-394, 2009.
28. Wu R, de Faire U, Lemme C, Witztum JL, Frostegard J, Autoantibodies to oxLDL are decreased in individuals with borderline hypertension, Hypertension 33, 53-59, 1999.
29. Pierdomenico SD, Lapenna D, Guglielmi MD, Costantini F, Romano F, Schiavone C, et al, Arterial disease in dipper and nondipper hypertensive patients, Am J Hypertens 10(5), 511-518, 1997.
30. Maeda K, Yasunari K, Watanabe T, Nakamura M, Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure, Hypertens Res 28, 755-761, 2005.
31. Yildiz A, Gur M, Demirbag R, Yilmaz R, Akyol S, Asian M, Erel O, Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients, Clinical Biochemistry 41, 779-784, 2008.
32. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN, Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase, J Clin Invest 101, 1581-1590, 1998.
33. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP, Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats, Hypertension 46, 82-86,2005.
34. Zhang ZH, Wei SG, Francis J, and Felder RB, Cardiovascular and renal sympathetic activation by blood-borne TNF in rat: the role of central prostaglandins, Am J Physiol Regul Integr Comp Physiol 284, 916-927, 2003.
35. Sanz-Rosa D, Oubina MP, Cediel E, De Las Heras N, Vegazo O, Jimenez J, et al, Effect of AT] receptor antagonism on vascular and circulating inflammatory mediators in SHR:role of NFKB/IKB system, Am J Physiol Heart Circ Physiol 288, 111-115, 2005.
36. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al., Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney, Kidney Int 82, 12-22, 2002.
37. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H, Plasma homocysteine is a determinant of tissue necrosis factor-a in hypertensive patients, Biomedicine & Pharmacotherapy 62, 360-365, 2008.